-transparent.png){kind=logo}
The paper reports the results of a randomized clinicoimmunological trial of domestic recombinant alpha 2-interferon (reaferon) in 30 patients with protracted viral hepatitis (27 subjects had viral hepatitis B and 3 patients HBV + HDV-coinfection). The reaferon treatment started on the disease week 7-8 and lasted for 2 months (1 x 10(6) IU, once a week, i.m.). VHB patients benefited from reaferon treatment as evident from improved clinical and laboratory indices, cases of complete cure and the agent elimination. In a protracted course of HBV + HDV coinfection reaferon in the above doses failed to produce any effect.
Related Publications
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
March 1990,
Klinicheskaia meditsina,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
January 1988,
Terapevticheskii arkhiv,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
January 1995,
Terapevticheskii arkhiv,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
July 1989,
Vrachebnoe delo,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
January 1991,
Terapevticheskii arkhiv,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
January 1996,
Klinicheskaia meditsina,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
March 1991,
Klinicheskaia meditsina,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
January 1992,
Pediatriia,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
April 1976,
Vrachebnoe delo,
L N Kokoreva, and
A V Zmyzgova, and
I V Nazarenko
January 1995,
Likars'ka sprava,
